Traders sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading hours on Monday. $59.93 million flowed into the stock on the tick-up and $84.82 million flowed out of the stock on the tick-down, for a money net flow of $24.89 million out of the stock. Of all stocks tracked, Pfizer had the 0th highest net out-flow for the day. Pfizer traded up $0.13 for the day and closed at $35.11

Several research analysts have weighed in on PFE shares. Goldman Sachs Group Inc. reiterated a “neutral” rating and set a $35.00 price objective on shares of Pfizer in a research report on Monday, April 18th. Vetr cut Pfizer from a “buy” rating to a “hold” rating and set a $34.19 price objective on the stock. in a research report on Tuesday, April 19th. BMO Capital Markets restated a “buy” rating on shares of Pfizer in a research report on Thursday, April 28th. Leerink Swann decreased their price target on Pfizer from $37.00 to $34.70 and set a “market perform” rating on the stock in a research report on Monday, May 2nd. Finally, Sanford C. Bernstein set a $36.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, May 3rd. Ten investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $38.17.

The firm has a market capitalization of $212.15 billion and a price-to-earnings ratio of 31.01. The firm has a 50 day moving average price of $35.92 and a 200 day moving average price of $32.98.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.02. During the same quarter in the prior year, the company earned $0.56 earnings per share. The business earned $13.10 billion during the quarter, compared to the consensus estimate of $13.01 billion. Pfizer’s revenue was up 10.9% compared to the same quarter last year. Analysts anticipate that Pfizer Inc. will post $2.46 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 1st. Shareholders of record on Friday, August 5th will be paid a $0.30 dividend. The ex-dividend date of this dividend is Wednesday, August 3rd. This represents a $1.20 dividend on an annualized basis and a yield of 3.42%.

In other news, EVP Frank A. Damelio sold 100,000 shares of the stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $34.49, for a total transaction of $3,449,000.00. Following the transaction, the executive vice president now directly owns 472,994 shares in the company, valued at approximately $16,313,563.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Loretta V. Cangialosi sold 86,000 shares of the stock in a transaction dated Tuesday, May 24th. The shares were sold at an average price of $33.97, for a total value of $2,921,420.00. Following the transaction, the vice president now owns 271,663 shares in the company, valued at $9,228,392.11. The disclosure for this sale can be found here.

Several institutional investors have recently made changes to their positions in the stock. Jackson Wealth Management LLC raised its position in shares of Pfizer by 0.4% in the fourth quarter. Jackson Wealth Management LLC now owns 51,115 shares of the biopharmaceutical company’s stock valued at $1,585,000 after buying an additional 214 shares during the period. Rowland & Co. Investment Counsel ADV boosted its stake in shares of Pfizer by 0.6% in the fourth quarter. Rowland & Co. Investment Counsel ADV now owns 60,161 shares of the biopharmaceutical company’s stock valued at $1,907,000 after buying an additional 358 shares in the last quarter. Bollard Group LLC boosted its stake in shares of Pfizer by 0.7% in the fourth quarter. Bollard Group LLC now owns 64,462 shares of the biopharmaceutical company’s stock valued at $2,081,000 after buying an additional 421 shares in the last quarter. Court Place Advisors LLC boosted its stake in shares of Pfizer by 0.8% in the fourth quarter. Court Place Advisors LLC now owns 67,070 shares of the biopharmaceutical company’s stock valued at $2,165,000 after buying an additional 515 shares in the last quarter. Finally, Holderness Investments Co. boosted its stake in shares of Pfizer by 0.8% in the fourth quarter. Holderness Investments Co. now owns 65,817 shares of the biopharmaceutical company’s stock valued at $2,125,000 after buying an additional 550 shares in the last quarter.

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.